- Home
- RDVT vs CRMD Comparison
RDVT vs CRMD Comparison
Compare RDVT & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDVT | CRMD |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 830.2M | 943.9M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | RDVT | CRMD |
|---|---|---|
| Price | $57.62 | $12.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $62.00 | $17.43 |
| AVG Volume (30 Days) | 103.6K | ★ 2.6M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | ★ 0.54% | N/A |
| EPS Growth | ★ 119.82 | N/A |
| EPS | 0.78 | ★ 2.25 |
| Revenue | $86,425,000.00 | ★ $214,303,672.00 |
| Revenue This Year | $20.55 | $627.89 |
| Revenue Next Year | $14.27 | $40.95 |
| P/E Ratio | $70.37 | ★ $5.56 |
| Revenue Growth | 22.27 | ★ 1647.67 |
| 52 Week Low | $32.23 | $5.60 |
| 52 Week High | $64.14 | $17.43 |
Technical Indicators
Market Signals| Indicator | RDVT | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 59.72 | 68.45 |
| Support Level | $54.83 | $11.78 |
| Resistance Level | $57.57 | $12.51 |
| Average True Range (ATR) | 2.21 | 0.50 |
| MACD | 0.20 | 0.14 |
| Stochastic Oscillator | 88.96 | 94.53 |
Price Performance
Historical ComparisonAbout RDVT Red Violet Inc.
Red Violet Inc is a software and services company. It specializes in data analysis, providing cloud-based, mission-critical information solutions to enterprises in a variety of industries. Through its CORE data fusion platform, it provides mission-critical information about individuals, businesses and assets.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.